Louisiana is currently home to 893 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172
Recruiting
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/16/2025
Locations: Ochsner Medical Center - Main Campus, New Orleans, Louisiana
Conditions: Intracranial Arteriosclerosis, Stroke
Register for Updates
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: CIS Clinical Research Corporation, Houma, Louisiana
Conditions: Peripheral Vascular Diseases
Register for Updates
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154
Recruiting
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/16/2025
Locations: Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana
Conditions: Chemotherapy-induced Thrombocytopenia
Register for Updates
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: * To enhance the understanding of the variability, progression, and natural history of F... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/16/2025
Locations: Ochsner Medical Center- Site Number : 840120, Baton Rouge, Louisiana
Conditions: Fabry Disease
Register for Updates
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610
Recruiting
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/15/2025
Locations: DelRicht LLC, Baton Rouge, Louisiana
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
PerQdisc Traditional Feasibility Trial.
NCT06860867
Recruiting
This is a traditional feasibility study (TFS) study to evaluate the safety and effectiveness of the PerQdisc. The study is prospective, multicenter, and open label. After a screening period, qualified participants will be enrolled and treated with the PerQdisc. Patients will not be blinded to their treatment. Participants will then complete the safety follow-up period.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
07/15/2025
Locations: Spine Institute of Louisiana, Shreveport, Louisiana
Conditions: Discogenic Low Back Pain
Register for Updates
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798
Recruiting
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Research Site, Kenner, Louisiana
Conditions: Delayed Graft Function, DGF, Kidney Transplant
Register for Updates
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/15/2025
Locations: Louisiana Research Center - GastroIntestinal Associates, Shreveport, Louisiana
Conditions: Moderately to Severely Active Crohns Disease
Register for Updates
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604
Recruiting
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/15/2025
Locations: Site Number - 1022, New Orleans, Louisiana
Conditions: Graves' Disease
Register for Updates
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
NCT06637072
Recruiting
This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Velocity Clinical Research, Lafayette, Louisiana
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743
Recruiting
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Southern Urology (Urology America), Lafayette, Louisiana
Conditions: High-Risk Non-Muscle-Invasive Bladder Cancer
Register for Updates
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360
Recruiting
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
07/15/2025
Locations: Tulane University Health Sciences Center, New Orleans, Louisiana
Conditions: NonSegmental Vitiligo
Register for Updates